# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 p...
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0....
Stifel analyst Bradley Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Targe...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 p...
Jefferies analyst Farzin Haque assumes Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 p...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.